MisterBlues schreef op 3 november 2020 16:01:DD_Police: Here is a post explaining why the sell-off:
Olav Zilian from Mirabaud Securities recommend to sell RLF shares on Monday. Reason is because phase II study for Phasebio's pemziviptadil showed no efficacy in 25 patients. "Based on the molecular profile of the two active ingredients, it seems likely to us that the active ingredient from Relief Therapeutics will also struggle to show effectiveness."
Dr. Javitt already explained last month in an interview (Dr. Yo Part 2) that Pemziviptadil will not work for Covid. Phasebio specifically designed it for use against Pulmonary Hypertension (for which it actually has a good chance of working). It is a subcutaneous injection of a VIP analogue designed to have a 60h half-life in the blood vs. 2 minutes for aviptadil. It specifically targets the VPAC2 receptor, while RLF-100 targets the VPAC1 receptor. That is why Dr. J said their product wouldn't work. And that is why @Tom explained all too well, why it wouldn't work for Covid. It isn't getting into the Type 2 cells in the lungs that need protection, produce surfactant, and inhibit SARS viral replication. Only the VPAC1 receptor gets VIP into the type 2 cells.
The Mirabaud Analyst is at best a completely incompetent biotech fool, or most likely a crooked banker. He knows the drug works, and wants his cronies to buy in as cheaply as possible.Repons Tom:
It’s shameful that the FDA even permitted the start of the study on PhaseBio’s drug PB1046. Both VIP & Aviptadil act on both the VPAC1 & VPAC2 receptors. PB1046 only acts on the VPAC2 receptors. It has no affinity for the VPAC1 receptors which are the receptors on the critical alveolar 2 cells The VPAC2 receptors are only in the lung blood vessels, not in the alveola.
The study of PB 1046 was doomed before it started. It’s shameful the FDA even permitted it to start.